You are here

  • Home
  • Archive
  • Volume 81, Issue 10
  • Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley

Citation Tools

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Potere N, Di Nisio M, Cibelli D, et al
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley
Annals of the Rheumatic Diseases 2022;81:e195.